Obesity-associated cancers: An emergent problem among younger adults ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
Back to Healio
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Back to Healio
The increasing prevalence and troubling consequences of obesity in the United States have been well-documented.
As Covid-19 cases surge, Multicare partners with startup to launch hospital-at-home program
Multicare rolled out a hospital-at-home program with Denver-based startup Dispatch Health. The program will free up hospital beds and staff as Covid-19 cases surge across the U.S.
Shares1
Dispatch health struck a partnership with Washington-based health system Multicare to offer a hospital-at-home program for its patients. Photo credit: DispatchHealth
As Covid-19 cases surge across the U.S., some hospitals are taking advantage of a new waiver from the Centers for Medicare and Medicaid Services that allows them to monitor patients at home. Multicare, a Washington-based health system, launched such a program in conjunction with Denver-based startup DispatchHealth.
Researchers identify new therapeutic target to treat patients with type 1 diabetes
Researchers at the University of Utah School of Medicine have identified a new therapeutic target to treat patients with type 1 diabetes. The study, which will be published December 9 in the
Journal of Experimental Medicine (
JEM), reveals that inhibiting a protein called OCA-B protects mice from type 1 diabetes by limiting the activity of immune cells that would otherwise destroy the pancreas insulin-producing β cells.
Type 1 diabetes is an autoimmune disease in which the body s immune system mistakenly attacks pancreatic β cells, cutting off the production of insulin. Patients require life-long insulin therapy to maintain appropriate blood glucose levels. At present, there are no treatments that can prevent the immune system from targeting β cells while preserving its ability to fight infection.